Compare EDIT & ASPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDIT | ASPN |
|---|---|---|
| Founded | 2013 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | RETAIL: Building Materials |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.8M | 418.5M |
| IPO Year | 2016 | 2011 |
| Metric | EDIT | ASPN |
|---|---|---|
| Price | $2.62 | $4.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $5.30 | $4.25 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.50 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $31,937,000.00 | ★ $271,103,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $50.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 132.64 | N/A |
| 52 Week Low | $1.66 | $2.30 |
| 52 Week High | $4.54 | $9.78 |
| Indicator | EDIT | ASPN |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 36.00 |
| Support Level | $2.36 | $3.01 |
| Resistance Level | $2.73 | $5.48 |
| Average True Range (ATR) | 0.21 | 0.27 |
| MACD | -0.08 | -0.05 |
| Stochastic Oscillator | 2.06 | 0.00 |
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology, supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Thermal Barrier segment and the United States market. Some of its products include Pyrogel XTE, Cryogel Z, Spaceloft Subsea, and others.